<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01720030</url>
  </required_header>
  <id_info>
    <org_study_id>Levosimendan in AKI Study</org_study_id>
    <nct_id>NCT01720030</nct_id>
  </id_info>
  <brief_title>Levosimendan in Acute Kidney Injury Study</brief_title>
  <acronym>LAKIS</acronym>
  <official_title>Prospective, Randomized, Monocenter, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Levosimendan in Intensive Care Patients With Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VieCuri Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VieCuri Medical Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesise that levosimendan will have a positive influence on renal function during
      acute kidney injury in adult intensive care patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to evaluate whether the use of levosimendan is able to improve
      renal function.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in renal function</measure>
    <time_frame>Baseline and every 24 hours until end ICU stay</time_frame>
    <description>Daily analysis of kidney function expressed in endogenous creatinine clearance</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Conventional therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care as protocolized locally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group receives standard treatment supplemented by levosimendan (0.2 Âµg/kg/min) for 24 hours within 36 hrs following onset of AKI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Verum therapy</description>
    <arm_group_label>Levosimendan</arm_group_label>
    <other_name>Simdax (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional therapy</intervention_name>
    <description>Placebo therapy to safeguard blinding</description>
    <arm_group_label>Conventional therapy</arm_group_label>
    <other_name>Standard care plus placebo comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed adult patients with AKI

        Exclusion Criteria:

          -  Failure to obtain written consent to participate from patient or legal representative
             (by deferred consent)

          -  Patients entering the ICU for post-operative observation with an estimated length of
             stay less than 24 hrs.

          -  Moribund patients

          -  Patients under the age of 18

          -  Pregnancy

          -  Patients suffering from pre-existing renal failure (elevated NGAL values without
             apparent rise in creatinine values)

          -  Renal replacement therapy initiated before admission due to Chronic Kidney Disease

          -  Hypersensitivity to levosimendan experienced by previous treatments

          -  Severe hypotension and tachycardia

          -  Significant mechanical obstruction affecting ventricular filling or outflow or both.

          -  Severe hepatic impairment (ALAT/ASAT&gt;400U/L)

          -  Patients will be excluded if the treating physician judges that study participation is
             undesirable for medical, medical-ethical or other reasons

          -  Known history of Torsades de Pointes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jos Le Noble, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VieCuri Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VieCuri Medical Center</name>
      <address>
        <city>Venlo</city>
        <state>Limburg</state>
        <zip>NL-5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2012</study_first_submitted>
  <study_first_submitted_qc>October 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2012</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VieCuri Medical Centre</investigator_affiliation>
    <investigator_full_name>Dr. Jos le Noble</investigator_full_name>
    <investigator_title>PhD, MD</investigator_title>
  </responsible_party>
  <keyword>Renal</keyword>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>AKI</keyword>
  <keyword>Levosimendan</keyword>
  <keyword>Simdax</keyword>
  <keyword>Renal perfusion</keyword>
  <keyword>Mortality</keyword>
  <keyword>Renal flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

